CALGARY, Alberta--(BUSINESS WIRE)--Pembina Pipeline Corporation ("Pembina") (TSX: PPL; NYSE: PBA) announced today that none of Pembina's Cumulative Redeemable Rate Reset Class A Preferred Shares, Series 3 ("Series 3 Shares") (TSX: PPL.PR.C) will be converted into Cumulative Redeemable Floating Rate...
GAAP earnings per share were $2.78 in 2023 compared to $2.73 in 2022
Temperature-normalized non-GAAP earnings per share were $2.88 in 2023 compared to $2.73 in 2022, representing 5.5% growth
Affirmed 2024 earnings guidance range of $2.99 - $3.13 per share
MADISON,...
KENOSHA, Wis.--(BUSINESS WIRE)--The Snap-on Incorporated (NYSE: SNA) board of directors declared today a quarterly common stock dividend of $1.86 per share payable March 11, 2024, to shareholders of record at the close of business on February 26, 2024. Snap-on...
MELBOURNE, Fla.--(BUSINESS WIRE)--Five missile tracking satellites L3Harris Technologies (NYSE:LHX) designed and built successfully launched from Cape Canaveral Space Force Station, Florida, as part of the Missile Defense Agency’s (MDA) Hypersonic and Ballistic Tracking Space Sensor (HBTSS) program and the...
Recognized for contributions to technological innovation and societal progressTOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that Dr. Shumpei Kameyama of Mitsubishi Electric’s Information Technology R&D Center (Kamakura, Japan) and Dr. Jonathan Le Roux of Mitsubishi Electric Research Laboratories,...
MILWAUKEE--(BUSINESS WIRE)--REV Group, Inc. (NYSE:REVG) announced today the pricing of the previously announced underwritten public offering, which has been upsized to 16,000,000 shares of common stock by certain selling stockholders at the public offering price of $16.50 per share....
SAN FRANCISCO--(BUSINESS WIRE)--Chef Robotics, the creator of ChefOS, the AI Brain for food manipulation, announced today that its ChefOS Enabled Robots in production have achieved a major milestone as of January 2024: more than 10M meals in production. This...
The U.S. Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate to severe atopic dermatitis.
Nemolizumab was granted U.S. FDA Priority...
TORONTO & SAN FRANCISCO--(BUSINESS WIRE)--Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advancing novel first-in-class medicines for unmet needs in cancer, today announced the formation of a Scientific Advisory Board comprised of prominent oncology leaders and drug...